Literature DB >> 22680836

Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea--a double-blind study.

R Francavilla1, E Lionetti, S Castellaneta, F Ciruzzi, F Indrio, A Masciale, C Fontana, M M La Rosa, L Cavallo, A Francavilla.   

Abstract

BACKGROUND: Probiotics may be of help for the management of acute diarrhoea, however, the effect is strain specific and efficacy needs to be proven. AIM: To test the efficacy and safety of Lactobacillus reuteri DSM 17938 derived from L. reuteri ATCC 55730 in children with acute diarrhoea. Primary outcomes were the rate of unresolved diarrhoea after 3 days of treatment and duration of diarrhoea.
METHODS: Children (6-36 months), hospitalised in three paediatric hospitals in Southern Italy for acute diarrhoea with clinical signs of dehydration were randomised to receive in a double-blind fashion either L. reuteri (dose of 4 × 10(8) colony-forming units/die) or placebo.
RESULTS: Out of 96 eligible children, 74 were enrolled, five patients were withdrawn; 35 in the L. reuteri group and 34 in the placebo group. Lactobacillus reuteri significantly reduced the duration of watery diarrhoea as compared with placebo (2.1 ± 1.7 days vs. 3.3 ± 2.1 days; P < 0.03); on day two and three of treatment watery diarrhoea persisted in 82% and 74% of the placebo and 55% and 45% of the L. reuteri recipients respectively (P < 0.01; P < 0.03). Finally, children receiving L. reuteri had a significantly lower relapse rate of diarrhoea (15% vs. 42%; P < 0.03). There was not a significant difference in hospital stay between the groups. No adverse events were recorded.
CONCLUSION: Our study shows that L . reuteri DSM 17938 as an adjunct to rehydration therapy is efficacious in the treatment of acute diarrhoea reducing the frequency, duration and recrudescence rate of the disease.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22680836     DOI: 10.1111/j.1365-2036.2012.05180.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  34 in total

1.  Lactobacillus reuteri DSM 17938 feeding of healthy newborn mice regulates immune responses while modulating gut microbiota and boosting beneficial metabolites.

Authors:  Yuying Liu; Xiangjun Tian; Baokun He; Thomas K Hoang; Christopher M Taylor; Eugene Blanchard; Jasmin Freeborn; Sinyoung Park; Meng Luo; Jacob Couturier; Dat Q Tran; Stefan Roos; Guoyao Wu; J Marc Rhoads
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-09-04       Impact factor: 4.052

2.  The Role of Probiotics in the Treatment of Dysentery: a Randomized Double-Blind Clinical Trial.

Authors:  Alireza Sharif; Hamed Haddad Kashani; Elahe Nasri; Zahra Soleimani; Mohammad Reza Sharif
Journal:  Probiotics Antimicrob Proteins       Date:  2017-12       Impact factor: 4.609

3.  Pan-Genomic Approaches in Lactobacillus reuteri as a Porcine Probiotic: Investigation of Host Adaptation and Antipathogenic Activity.

Authors:  Jun-Yeong Lee; Geon Goo Han; Jaeyun Choi; Gwi-Deuk Jin; Sang-Kee Kang; Byung Jo Chae; Eun Bae Kim; Yun-Jaie Choi
Journal:  Microb Ecol       Date:  2017-04-24       Impact factor: 4.552

4.  Escherichia coli Nissle 1917 protects gnotobiotic pigs against human rotavirus by modulating pDC and NK-cell responses.

Authors:  Anastasia N Vlasova; Lulu Shao; Sukumar Kandasamy; David D Fischer; Abdul Rauf; Stephanie N Langel; Kuldeep S Chattha; Anand Kumar; Huang-Chi Huang; Gireesh Rajashekara; Linda J Saif
Journal:  Eur J Immunol       Date:  2016-08-11       Impact factor: 5.532

Review 5.  Comparison of probiotic lactobacilli and bifidobacteria effects, immune responses and rotavirus vaccines and infection in different host species.

Authors:  Anastasia N Vlasova; Sukumar Kandasamy; Kuldeep S Chattha; Gireesh Rajashekara; Linda J Saif
Journal:  Vet Immunol Immunopathol       Date:  2016-01-14       Impact factor: 2.046

6.  AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders.

Authors:  Geoffrey A Preidis; Adam V Weizman; Purna C Kashyap; Rebecca L Morgan
Journal:  Gastroenterology       Date:  2020-06-09       Impact factor: 22.682

7.  Probiotics and prebiotics in infants and children.

Authors:  Y Vandenplas; E De Greef; T Devreker; G Veereman-Wauters; B Hauser
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

Review 8.  Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

9.  Probiotic and Functional Properties of Limosilactobacillus reuteri INIA P572.

Authors:  Patricia Diez-Echave; Izaskun Martín-Cabrejas; José Garrido-Mesa; Susana Langa; Teresa Vezza; José M Landete; Laura Hidalgo-García; Francesca Algieri; Melinda J Mayer; Arjan Narbad; Ana García-Lafuente; Margarita Medina; Alba Rodríguez-Nogales; María Elena Rodríguez-Cabezas; Julio Gálvez; Juan L Arqués
Journal:  Nutrients       Date:  2021-05-29       Impact factor: 6.706

10.  An oral preparation of Lactobacillus acidophilus for the treatment of uncomplicated acute watery diarrhoea in Vietnamese children: study protocol for a multicentre, randomised, placebo-controlled trial.

Authors:  Marion-Eliëtte Kolader; Ha Vinh; Pham Thi Ngoc Tuyet; Corinne Thompson; Marcel Wolbers; Laura Merson; James I Campbell; Tran Thi Ngoc Dung; Ha Manh Tuan; Nguyen Van Vinh Chau; Jeremy Farrar; H Rogier van Doorn; Stephen Baker
Journal:  Trials       Date:  2013-01-28       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.